These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 39309666)

  • 1. DPD Quantification Correlates With Extracellular Volume and Disease Severity in Wild-Type Transthyretin Cardiac Amyloidosis.
    Rettl R; Calabretta R; Duca F; Kronberger C; Binder C; Willixhofer R; Poledniczek M; Hofer F; Doná C; Beitzke D; Loewe C; Nitsche C; Hengstenberg C; Badr Eslam R; Kastner J; Bergler-Klein J; Hacker M; Kammerlander AA
    JACC Adv; 2024 Oct; 3(10):101261. PubMed ID: 39309666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.
    Rettl R; Wollenweber T; Duca F; Binder C; Cherouny B; Dachs TM; Camuz Ligios L; Schrutka L; Dalos D; Beitzke D; Loewe C; Badr Eslam R; Kastner J; Hacker M; Bonderman D
    Eur Heart J Cardiovasc Imaging; 2023 Jul; 24(8):1019-1030. PubMed ID: 36881774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in
    Rettl R; Calabretta R; Duca F; Binder C; Kronberger C; Willixhofer R; Poledniczek M; Donà C; Nitsche C; Beitzke D; Loewe C; Auer-Grumbach M; Bonderman D; Kastl S; Hengstenberg C; Badr Eslam R; Kastner J; Bergler-Klein J; Hacker M; Kammerlander A
    Amyloid; 2024 Mar; 31(1):42-51. PubMed ID: 37599395
    [No Abstract]   [Full Text] [Related]  

  • 4. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
    Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging.
    Chamling B; Bietenbeck M; Korthals D; Drakos S; Vehof V; Stalling P; Meier C; Yilmaz A
    Clin Res Cardiol; 2023 Mar; 112(3):353-362. PubMed ID: 35666277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitation of
    Ross JC; Hutt DF; Burniston M; Page J; Steeden JA; Gillmore JD; Wechalekar AD; Hawkins PN; Fontana M
    Amyloid; 2018 Sep; 25(3):203-210. PubMed ID: 30486686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac transthyretin amyloidosis
    Löfbacka V; Axelsson J; Pilebro B; Suhr OB; Lindqvist P; Sundström T
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1822-1832. PubMed ID: 33367948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid.
    Hutt DF; Fontana M; Burniston M; Quigley AM; Petrie A; Ross JC; Page J; Martinez-Naharro A; Wechalekar AD; Lachmann HJ; Quarta CC; Rezk T; Mahmood S; Sachchithanantham S; Youngstein T; Whelan CJ; Lane T; Gilbertson JA; Rowczenio D; Hawkins PN; Gillmore JD
    Eur Heart J Cardiovasc Imaging; 2017 Dec; 18(12):1344-1350. PubMed ID: 28159995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study.
    Aimo A; Vergaro G; Castiglione V; Fabiani I; Barison A; Gentile F; Ferrari Chen YF; Giorgetti A; Genovesi D; Buda G; Franzini M; Piepoli M; Moscardini S; Rapezzi C; Fontana M; Passino C; Emdin M
    Eur J Prev Cardiol; 2024 Aug; 31(11):1410-1417. PubMed ID: 38456769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of [
    Caobelli F; Gözlügöl N; Bakula A; Rominger A; Schepers R; Stortecky S; Hunziker Munsch L; Dobner S; Gräni C
    J Nucl Med; 2024 Jun; 65(6):944-951. PubMed ID: 38724281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac MRI T1 and T2 Mapping as a Quantitative Imaging Biomarker in Transthyretin Amyloid Cardiomyopathy.
    Yamaguchi S; Oda S; Kidoh M; Hayashi H; Takashio S; Usuku H; Nagayama Y; Nakaura T; Tsujita K; Hirai T; Aoki T
    Acad Radiol; 2024 Feb; 31(2):514-522. PubMed ID: 37775448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DPD Quantification in Cardiac Amyloidosis: A Novel Imaging Biomarker.
    Scully PR; Morris E; Patel KP; Treibel TA; Burniston M; Klotz E; Newton JD; Sabharwal N; Kelion A; Manisty C; Kennon S; Ozkor M; Mullen M; Hartman N; Elliott PM; Pugliese F; Hawkins PN; Moon JC; Menezes LJ
    JACC Cardiovasc Imaging; 2020 Jun; 13(6):1353-1363. PubMed ID: 32498921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis.
    Hutt DF; Quigley AM; Page J; Hall ML; Burniston M; Gopaul D; Lane T; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
    Eur Heart J Cardiovasc Imaging; 2014 Nov; 15(11):1289-98. PubMed ID: 24939945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue mapping by cardiac magnetic resonance imaging for the prognostication of cardiac amyloidosis: A systematic review and meta-analysis.
    Cai S; Haghbayan H; Chan KKW; Deva DP; Jimenez-Juan L; Connelly KA; Ng MY; Yan RT; Yan AT
    Int J Cardiol; 2024 May; 403():131892. PubMed ID: 38382853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exercise Hemodynamics and Mitochondrial Oxidative Capacity in Disease Stages of Wild-Type Transthyretin Amyloid Cardiomyopathy.
    Ladefoged B; Pedersen AD; Seefeldt J; Nielsen BRR; Eiskjær H; Lichscheidt E; Clemmensen T; Gillmore JD; Poulsen SH
    J Am Heart Assoc; 2024 Jul; 13(13):e034213. PubMed ID: 38934860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosing cardiac amyloidosis in every-day practice: A practical guide for the cardiologist.
    Papathanasiou M; Carpinteiro A; Rischpler C; Hagenacker T; Rassaf T; Luedike P
    Int J Cardiol Heart Vasc; 2020 Jun; 28():100519. PubMed ID: 32373710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive risk stratification of patients with transthyretin amyloidosis.
    Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
    JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic Resonance in Transthyretin Cardiac Amyloidosis.
    Martinez-Naharro A; Treibel TA; Abdel-Gadir A; Bulluck H; Zumbo G; Knight DS; Kotecha T; Francis R; Hutt DF; Rezk T; Rosmini S; Quarta CC; Whelan CJ; Kellman P; Gillmore JD; Moon JC; Hawkins PN; Fontana M
    J Am Coll Cardiol; 2017 Jul; 70(4):466-477. PubMed ID: 28728692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A compartment-based myocardial density approach helps to solve the native T1 vs. ECV paradox in cardiac amyloidosis.
    Chamling B; Bietenbeck M; Drakos S; Korthals D; Vehof V; Stalling P; Meier C; Yilmaz A
    Sci Rep; 2022 Dec; 12(1):21755. PubMed ID: 36526658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.